|
| Status |
Public on Jul 09, 2019 |
| Title |
Response of triple negative breast cancer to BAZ2A/B inhibition and BET bromodomain inhibition alone and in combination (RNAseq) |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Three triple negative breast cancer cell lines (MDAMB231, SUM159, and HCC1806) were treated with small molecule inhibitors (JQ1, BET bromodomain inhibitor; GSK2801, BAZ2A/B bromodomain inhibitor) alone and in combination for 72 hours
|
| |
|
| Overall design |
12 experimental samples
|
| |
|
| Contributor(s) |
Johnson GL, Bevill SM |
| Citation(s) |
31000582 |
| |
| Submission date |
Jul 10, 2018 |
| Last update date |
Oct 08, 2019 |
| Contact name |
Bradley E Bernstein |
| E-mail(s) |
Bradley_bernstein@dfci.harvard.edu
|
| Organization name |
Dana Farber Cancer Institute
|
| Department |
Cancer Biology
|
| Lab |
Bradley Bernstein
|
| Street address |
450 Brookline Ave
|
| City |
Boston |
| State/province |
Massachusetts |
| ZIP/Postal code |
02215 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL18573 |
Illumina NextSeq 500 (Homo sapiens) |
|
| Samples (12)
|
|
| This SubSeries is part of SuperSeries: |
| GSE116919 |
Response of triple negative breast cancer to BAZ2A/B inhibition and BET bromodomain inhibition alone and in combination |
|
| Relations |
| BioProject |
PRJNA480603 |
| SRA |
SRP153037 |
Less...
More...